H.C. Wainwright Maintains A Buy Rating On Wave Life Sciences Ltd. (WVE) [Yahoo! Finance]
Wave Life Sciences Ltd. - Ordinary Shares (WVE)
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.wavelifesciences.com/news-releases?page=1%2c0%2c0%2c0
Company Research
Source: Yahoo! Finance
Wainwright upgraded Wave Life Sciences Ltd. (NASDAQ:WVE)'s price target from $22 to $30. Analyst Andrew Fein upheld the Buy rating. H.C. Wainwright cited 9.4% visceral fat loss and 3.2% lean mass gain with no gastrointestinal problems to support WVE-007 as a possible body recomposition agent, using key opinion leader validation and dose-response modeling. According to the firm, higher doses may expedite fat loss, and a clean safety profile supports a distinct commercial label. Visible Alpha reported on the same day that Wave Life Sciences Ltd. (NASDAQ:WVE) shares soared by 147% on December 8 following the company's presentation of preliminary clinical data for WVE-007, an RNA-based obesity therapy. Three months after a single dose, early data from a small research study revealed sustained fat reduction, including drops in visceral and total fat. Visible Alpha consensus forecasts that risk-adjusted revenue for WVE-007 is expected to increase from $26 million to approximately $68 mi
Show less
Read more
Impact Snapshot
Event Time:
WVE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WVE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WVE alerts
High impacting Wave Life Sciences Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
WVE
News
- Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing PortfolioGlobeNewswire
- WAVE Life Sciences (NASDAQ:WVE) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=WVE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZMarketBeat
- Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- WAVE Life Sciences (NASDAQ:WVE) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=WVE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
WVE
Earnings
- 11/10/25 - Miss
WVE
Sec Filings
- 1/12/26 - Form 8-K
- 1/6/26 - Form 4
- 12/15/25 - Form SCHEDULE
- WVE's page on the SEC website